ID: ALA470194

Max Phase: Preclinical

Molecular Formula: C20H17NO3S

Molecular Weight: 351.43

Molecule Type: Small molecule

Representations

Synonyms (1): AM-2S
Synonyms from Alternative Forms(1):

Canonical SMILES:  Cc1cc(=S)c(O)c(C(=O)NCc2ccc(-c3ccccc3)cc2)o1

Standard InChI:  InChI=1S/C20H17NO3S/c1-13-11-17(25)18(22)19(24-13)20(23)21-12-14-7-9-16(10-8-14)15-5-3-2-4-6-15/h2-11,22H,12H2,1H3,(H,21,23)

Standard InChI Key:  ZOMMNLRHGAAUNM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 351.43

Molecular Weight (Monoisotopic): 351.0929

AlogP: 4.62

#Rotatable Bonds: 4

Polar Surface Area: 62.47

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.11

CX Basic pKa:

CX LogP: 3.85

CX LogD: 3.85

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.67

Np Likeness Score: -0.75

References

1. Yan YL, Miller MT, Cao Y, Cohen SM..  (2009)  Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.,  19  (7): [PMID:19261472] [10.1016/j.bmcl.2009.02.044]

2. Arshad JZ, Hanif M..  (2022)  Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.,  13  (10.0): [PMID:36325396] [10.1039/d2md00175f]

Source

Source(1):

• Scientific Literature